Brokerages forecast that Myovant Sciences Ltd (NYSE:MYOV) will report ($0.80) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Myovant Sciences’ earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.73). Myovant Sciences reported earnings of ($0.99) per share during the same quarter last year, which would suggest a positive year over year growth rate of 19.2%. The firm is expected to issue its next quarterly earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($3.14) per share for the current financial year, with EPS estimates ranging from ($3.44) to ($2.92). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.75) per share, with EPS estimates ranging from ($3.03) to ($2.52). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Myovant Sciences.
MYOV has been the topic of a number of recent analyst reports. Svb Leerink initiated coverage on Myovant Sciences in a research report on Monday, August 19th. They set an “outperform” rating and a $26.00 price target on the stock. ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Goldman Sachs Group set a $18.00 price target on Myovant Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Zacks Investment Research downgraded Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Finally, Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday, September 6th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $21.89.
NYSE MYOV traded down $0.33 during trading on Friday, reaching $5.53. 200,561 shares of the company’s stock were exchanged, compared to its average volume of 259,714. The business has a 50 day moving average price of $5.16 and a 200-day moving average price of $8.69. The stock has a market capitalization of $511.74 million, a P/E ratio of -1.35 and a beta of 0.91. The company has a debt-to-equity ratio of 1.24, a current ratio of 3.42 and a quick ratio of 3.42. Myovant Sciences has a fifty-two week low of $4.14 and a fifty-two week high of $26.02.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Further Reading: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.